Purpose / DescriptionIn this open-label, dual-arm phase 3 trial, 137 noncirrhotic adults with HCV (genotype 1-6) and HIV coinfection were assigned 8 weeks of glecaprevir-pibrentasvir and 16 coinfected patients with compensated cirrhosis received 12 weeks of glecaprevir-pibrentasvir. The majority (63%) of participants had genotype 1 infection; 18% were treatment-experienced (16% with interferon and 2% were sofosbuvir based). All but 10 patients were taking either raltegravir, dolutegravir or rilpivirine as the anchor drug for antiretroviral therapy. The overall sustained virologic response rate was 98%; one patient with genotype 3 with cirrhosis experienced on-treatment virologic breakthrough.